Mode of Action Studies

  • Annemarie Polak
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 96)

Abstract

There are two approaches to the discovery of new antifungal drugs: the rational and the empirical. Up to now, none of the antifungal drugs available has been found on the basis of a truly rational approach. This may largely be explained by the unfortunate fact that fungi, like their human hosts, are eucaryotic organisms and hence the number of potential targets for specific drug action is limited. Furthermore, basic research on the biochemistry and physiology of the fungal cell was until recently rather neglected in contrast to the profound biochemical knowledge accumulated for bacterial cells. For a successful rational approach to designing antifungals it is important that detailed knowledge of the enzymatic steps used by fungal cells be available. Besides basic research on the biochemistry of fungi, mode of action studies with existing antimycotics may contribute to a deeper insight into the meta-bolism of fungal cells. Such mode of action studies are urgently needed and should not only be performed in industrial laboratories but also in an academic environment.

Keywords

Streptomyces Pyrimidine Thymidine Cytosine Maltose 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arai T, Mikami T, Yokoyama K, Kawata T (1977) Morphological changes in yeasts as a result of the action of 5-fluorocytosine. Antimicrob Agents Chemother 12: 255–260PubMedGoogle Scholar
  2. Baguley BC, Römmele G, Gruner J, Wehrli W (1979) Papulacandin B: an inhibitor of glucan synthesis in yeast spheroplasts. Eur J Biochem 97: 345–351PubMedCrossRefGoogle Scholar
  3. Baloch RI, Mercer EI (1987) Inhibition of sterol Δ8–Δ7-isomerase and Δ14-reductase by fenpropimorph, tridemorph and fenpropidin in cell-free enzyme systems from Saccharomyces cerevisiae. Phytochem 26: 663–668CrossRefGoogle Scholar
  4. Barrett-Bee KJ, Lane AC, Turner RW (1986) The mode of antifungal action of tolnaftate. J Med Vet Mycol 24: 155–160PubMedCrossRefGoogle Scholar
  5. Borgers M (1985) Antifungal azole derivatives. In: Greenwood D, O’Grady F (eds) Borgers M, pp 133–153 ( Thirty-eighth symposium of the Society for General Microbiology )Google Scholar
  6. Borgers M, Van de Ven MA (1987) Degenerative changes in fungi after itraconazole treatment. Rev Inf Dis 9: S33–S42Google Scholar
  7. Brasseur R, Vandenbosch C, Vanden Bossche H, Ruysschaert JM (1983) Mode of insertion of miconazole, ketoconazole and deacylated ketoconazole in lipid layers. Biochem Pharmacol 32: 2175–2180PubMedCrossRefGoogle Scholar
  8. Chen WC, Chou DL, Feingold DS (1978) Dissociation between ion permeability and the lethal action of polyene antibiotics on Candida albicans. Antimicrob Agents Chemother 13: 914–917PubMedGoogle Scholar
  9. Cohen SS, Barner HD (1954) Studies on unbalanced growth in Escherichia coli. Proc Natl Acad Sci USA 40: 885–893PubMedCrossRefGoogle Scholar
  10. Cohen SS, Flaks JG, Barner HD, Loeb MR, Lichtenstein J (1958) The mode of action of 5-fluorouracil and its derivatives. Proc Natl Acad Sci USA 44: 1004–1012PubMedCrossRefGoogle Scholar
  11. De Kruijff B, Gerritsen WJ, Oerlemans A, van Dijck PWM, Demel RA, Deenen LLM (1974) Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes. II. Temperature dependence of the polyene antibiotic-sterol complex formation. Biochim Biophys Acta 339: 44–56Google Scholar
  12. El-Nakeeb MY, Lampen JO (1965) Uptake of 3H-griseofulvin by micro-organisms and its correlation with sensitivity to griseofulvin. J Gen Microbiol 39: 285–293PubMedGoogle Scholar
  13. Gale E (1986) Nature and development of phenotypic resistance to amphotericin B in Candida albicans. Adv Microb Physiol 27: 278–320Google Scholar
  14. Giege R, Weil J-H (1970) Etude des tRNA de levure ayant incorporé du 5-fluoroura- cile provenant de la désamination in vivo de la 5-fluorocytosine. Bull Soc Chim Biol 52: 135–144PubMedGoogle Scholar
  15. Gordee RS, Zeckner DJ, Ellis LF (1984) In vitro and in vivo anti-Candida activity and toxicology of LY 121019. J Antibiot 37: 1054–1065PubMedGoogle Scholar
  16. Grisham LM, Wilson L, Bensch KG (1973) Antimitotic action of griseofulvin does not involve disruption of microtubules. Nature 244: 294–296PubMedCrossRefGoogle Scholar
  17. Gull K, Trinci APJ (1973) Griseofulvin inhibits fungal mitosis. Nature 244: 292–294PubMedCrossRefGoogle Scholar
  18. Iwata K, Yamamoto Y, Yamaguchi H, Hiratani T (1982) In vitro studies of aculeacin A, a new antifungal antibiotic. J Antibiot 35: 203–209PubMedGoogle Scholar
  19. Jund R, Lacroute F (1974) Génétique et physiologie de la résistance aux 5-fluoropyri- midines chez Saccharomyces cerevisiae. Bull Soc Franc Mycol Médicale 111: 5–8Google Scholar
  20. Kerkenaar A (1987) The mode of action of dimethylmorpholines. In: Fromtling RA (ed) Recent trends in the discovery, development and evaluation of antifungal agents. JR Prous, Barcelona, pp 523–542Google Scholar
  21. Kerridge D (1986) Mode of action of clinically important antifungal drugs. Adv Microb Physiol 27: 1–72.PubMedCrossRefGoogle Scholar
  22. Kotler-Brajtburg J, Price HD, Medoff G, Schiessinger D, Kobayashi GS (1974) Molecular basis for the selective toxicity of amphotericin B for yeast and filipin for animal cells. Antimicrob Agents Chemother 5: 377–382PubMedGoogle Scholar
  23. Lampen JO (1966) Interference by polyene antibiotics (especially nystatin and filipin) with specific membrane functions. In: Newton BA, Reynolds PE (eds) Lampen JO, pp 111–130 ( Sixteenth symposium of the Society for General Microbiology )Google Scholar
  24. Lampen JO, Arnow PM, Borowska Z, Laskin AI (1962) Location and role of sterol at 180 nystatin-binding sites. J Bacteriol 84: 1152–1160PubMedGoogle Scholar
  25. Malawista SE (1973) Microtubules and the movement of melanin granules in frog dermal melanocytes. Ann NY Acad Sci 253: 702–710CrossRefGoogle Scholar
  26. Marini F, Arnow P, Lampen PO (1961) The effect of monovalent cations on the inhibition of yeast metabolism by nystatin. J Gen Microbiol 24: 51–62PubMedGoogle Scholar
  27. Medoff G, Kobayashi G A (1980) Antifungal agents - the polyenes. In: Speller DCE (ed) Antifungal chemotherapy. Wiley & Sons, Chichester, pp 3–33Google Scholar
  28. Meingassner JG, Sleytr UB (1982) The effects of naftifme on the ultrastructure of Candida parapsilosis: a freeze fracture study. Sabouraudia 20: 199–207PubMedCrossRefGoogle Scholar
  29. Meingassner JG, Sleytr UB, Petranyi G (1981) Morphological changes induced by naftifine, a new antifungal agent, in Trichophyton mentagrophytes. J Invest Dermatol 77: 444–451PubMedCrossRefGoogle Scholar
  30. Müller J, Polak A, Jaeger R (1987) The effect of the morpholine derivate amorolfin (Roche 14–4767/002) on the ultrastructure of Candida albicans. Mykosen 30: 528–540PubMedGoogle Scholar
  31. Nes WR, Sekula BC, Nes D, Adler JH (1978) The functional importance of structural features of ergosterol in yeast. J Biol Chem 253: 6218–6225PubMedGoogle Scholar
  32. Osterman DG, DePhillis GD, Wu JC, Matsuda A, Santi DV (1988) 5-Fluorocytosine in DNA is a mechanism-based inhibitor of Hhal methylase. Biochemistry 27: 5204–5210Google Scholar
  33. Palacios J, Serrano R (1978) Proton permeability induced by polyene antibiotics. A plausible mechanism for their inhibition of maltose fermentation in yeast. FEBS Lett 91: 198–201PubMedCrossRefGoogle Scholar
  34. Perez P, Varona R, Garcia-Acha I, Duran A (1981) Effect of papulacandin B and aeuleacin A on P-(l,3)-glucan-synthase from Geotrichum lactis. FEBS Lett 129: 249–252CrossRefGoogle Scholar
  35. Plempel M, Berg D (1984) Reduction of the in vitro virulence of Candida albicans by pre treatment with subinhibitory azole concentrations in vitro. Dermatologica 169 [Suppl.L]:11–18Google Scholar
  36. Polak A (1988a) Mode of action of 5-fiuorocytosine in Aspergillus fumigatus. In: Vanden Bossche H, Mackenzie DWR, Cauwenbergh G (eds) Aspergillus and aspergillosis. Plenum, New York, p 165Google Scholar
  37. Polak A (1988b) Mode of action of morpholine derivatives. Ann N Y Acad Sci 544: 221–228PubMedCrossRefGoogle Scholar
  38. Polak A, Scholer H J (1975) Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 21: 113–130PubMedCrossRefGoogle Scholar
  39. Polak A, Scholer HJ (1980) Mode of action of 5-fluorocytosine. Rev Inst Past Lyon 13: 233–244Google Scholar
  40. Polak-Wyss A, Lengseld H, Oesterhelt G (1985) Effect of oxiconazole and Ro 14–4767/002 on sterol pattern in Candida albicans. Sabouraudia: J Med Vet My col 23: 433–442Google Scholar
  41. Rodriguez RJ, Parks LW (1983) Structural and physiological features of sterols necessary to satisfy bulk membrane and sparking requirements in yeast sterol auxotrophs. Arch Biochem Biophys 225: 861–871PubMedCrossRefGoogle Scholar
  42. Römmele G, Traxler P, Wehrli W (1983) Papulacandins - the relationship between chemical structure and effect on glucan synthesis in yeast. J Antibiotics 36: 1539–1542Google Scholar
  43. Ryder N (1984) Selective inhibition of squalene epoxidation by allylamine antimycotic agents. In: Nombela C (ed) Microbial cell wall synthesis and autolysis. Elsevier, Amsterdam, p 313Google Scholar
  44. Ryder N (1985a) Specific inhibition of fungal sterol biosynthesis by SF 86–327, a new allylamine antimycotic agent. Antimicrob Agents Chemother 27: 252–256PubMedGoogle Scholar
  45. Ryder N (1985b) Effect of allylamine antimycotic agents on fungal sterol biosynthesis measured by sterol side-chain methylation. J Gen Microbiol 131: 1595–1602PubMedGoogle Scholar
  46. Ryder NS, Dupont MC (1985) Inhibition of squalene epoxidase by allylamine anti-mycotic compounds. A comparative study of the fungal and mammalian enzymes. Biochem J 230: 765–770PubMedGoogle Scholar
  47. Ryder NS, Frank I, Dupont MC (1986) Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate. Antimicrob Agents Chemother 29: 858–860PubMedGoogle Scholar
  48. Sawistowska-Schroder ET, Kerridge D, Perry H (1984) Echinocandin inhibition of 1,3-P-D-glucan synthase from Candida albicans. FEBS Letts 173: 134–138CrossRefGoogle Scholar
  49. Scholer H (1980) Flucytosine. In: Speller DCE (ed) Antifungal chemotherapy. Wiley & Sons, Chichester, pp 35–106Google Scholar
  50. Scholer HJ, Polak A (1984) Resistance to systemic antifungal agents. In: Bryan LE (ed) Antimicrobial drug resistance. Academic, Orlando, pp 393–460Google Scholar
  51. Shigematsu ML, Uno J, Arai T (1982) Effect of ketoconazole on isolated mitochondria from Candida albicans. Antimicrob Agents Chemother 21: 919–924PubMedGoogle Scholar
  52. Thomas AH (1986) Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother 17:269– 279Google Scholar
  53. Trzaskos JM, Henry MJ (1989) Comparative effects of the azole-based fungicide flusilazole on yeast and mammalian lanosterol 14a-methyl demethylase. Antimicrob Agents Chemother 33: 1228–1231PubMedGoogle Scholar
  54. Uno J, Shigematsu ML, Arai T (1982) Primary site of action of ketoconazole on Candida albicans. Antimicrob Agents Chemother 21: 912–918PubMedGoogle Scholar
  55. Vanden Bossche H, Ruysschaert JM, Defrise-Quertain F, Willemsens G, Cornelissen F, Maricahl P, Cools W, van Cutsem J (1982) The interaction of miconazole and ketoconazole with lipids. Biochem Pharmacol 31: 2509–2517Google Scholar
  56. Vanden Bossche H, Lauwers W, Willemsens G, Marichal P, Cornelisson F, Cools W (1984a) Molecular basis for the antimycotic and antibacterial activity of N- substituted imidazoles and triazoles: the inhibition of isoprenoid biosynthesis. Pesticide Sci 15: 188–198CrossRefGoogle Scholar
  57. Vanden Bossche H, Willemsens G, Marichal P, Cools W, Lauwers W (1984b) The molecular basis for the antifungal activities of N-substituted azole derivatives. Focus on R 51 211. In: Trinci APJ, Ryley JF (eds) Mode of action of antifungal agents. Cambridge University Press, Cambridge, pp 321–341 (Symposium no 9 of the British Mycological Society)Google Scholar
  58. Vanden Bossche H, Bellens D, Cools W, Gorrens J, Marichal P, Verhoeven H, Willemsens G, De Coster R, Beerens D, Haeltermann C, Coene MC, Lauwers W, Le Jeune L (1986) Cytochrome P–450: target for itraconazole. Drug Dev Res 8: 287–298CrossRefGoogle Scholar
  59. Varona R, Pérez P, Durán A (1983) Effect of papulacandin B on (3-glucan synthesis in Schizosaccharomyces pombe. FEMS Microbiol Lett 20: 243–247Google Scholar
  60. Wain WH, Polak A (1981) The effect of 5-fluorocytosine on the synthesis of 80S ribosomes by pathogenic fungi. Sabouraudia 19: 187–197PubMedCrossRefGoogle Scholar
  61. Waldorf AR, Polak A (1983) Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother 23: 79–85PubMedGoogle Scholar
  62. Whelan WL, Markie D, Kwong-Chung KJ (1986) Complementation analysis of resistance to 5-fluorocytosine in Candida albicans. Antimicrob Agents Chemother 29: 726–729PubMedGoogle Scholar
  63. Yamaguchi H, Iwata K (1979) Effect of fatty acyl group and sterol composition on sensitivity of lecithin liposomes to imidazole antimycotics. Antimicrob Agents Chemother 15: 706–711PubMedGoogle Scholar
  64. Yamaguchi H, Hiratani T, Iwata K, Yamamoto Y (1982) Studies on the mechanism of antifungal action of aculeacin A. J Antibiot 35: 210–219PubMedGoogle Scholar
  65. Zygmung WA, Tavormina PA (1966) Steroid interference with antifungal activity of polyene antibiotics. Applied Microb 14: 865–869Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Annemarie Polak

There are no affiliations available

Personalised recommendations